The results described here support the increasing body of evidence indicating that the addition of PEM treatment to ENZ therapy is associated with increased survival benefits in men with previously untreated mCRPC harbouring PD-L1 staining regardless of tumor mutation status. This evidence concerns the gene CD274 and neoplasm.